Background: Refractoriness to platelet transfusion, prevalent among 15-20% of hemato-oncological patients, is associated with multitransfusions and inferior outcomes. We evaluated the effectiveness of extended slow-dose transfusion (ESDT) in increasing platelet increments in multitransfused patients. Methods: Patients treated after the implementation of ESDT were compared with historical controls treated with standard single-donor platelet (SDP) transfusions. Cohorts of early and late recipients were assembled for comparison, i.e. the 8th or 9th and 11th platelet unit per patient, respectively. Patients in the ESDT group received transfusions equal to half an SDP unit, administered over 4 h. Effectiveness was defined as a higher corrected count increment (CCI) at 1, 12, and 24 h after transfusion. Results: In the early-recipients cohort, 24-h-posttransfusion increments were available for 29 ESDT patients and 6 standard patients, and did not differ significantly between the groups (p = 0.078). The 24-h-posttransfusion increment was available for 20 ESDT patients and 7 standard patients in the late-recipients cohort. The CCI was significantly higher in the ESDT group (p = 0.042). ABO compatibility improved the CCI (p = 0.01). Conclusions: ESDT demonstrated slightly higher increments at 24 h after transfusion in late recipients, suggesting this could be a cost-effective approach for the treatment of thrombocytopenic multitransfused hemato-oncological patients.

Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao K-J, Kickler T, Lee E, McFarland J, McCullough J: Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-4114.
Delaflor-Weiss E, Mintz PD: The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000;14:180-196.
Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R, Yuen K, Veale M, Whiteside MG, Cooper IA: Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-387.
Legler T, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, Riggert J, Schleyer E, Kern W, Hiddemann W: Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 1997;74:185-189.
Hod E, Schwartz J: Platelet transfusion refractoriness. Br J Haematol 2008;142:348-360.
McFarland J, Menitove J, Kagen L, Braine H, Kickler T, Ness P, Fuller A, Slichter S, Gernsheimer T, Townsend-McCall D: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869.
Toor A, Choo S, Little J: Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant 2000;26.
Kerkhoffs JLH, Eikenboom JC, Van De Watering LM, Wordragen-Vlaswinkel V, Rinie J, Wijermans PW, Brand A: The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008;48:1959-1965.
Meehan K, Matias C, Rathore S, Sandler S, Kallich J, LaBrecque J, Erder H, Schulman K: Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 2000;64:251-256.
Doughty H, Murphy M, Metcalfe P, Rohatiner A, Lister T, Waters A: Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200-205.
Davis KB, Slichter SJ, Corash L: Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 1999;39:586-592.
Bishop J, Matthews J, Yuen K, McGrath K, Wolf M, Szer J: The definition of refractoriness to platelet transfusions. Transfus Med 1992;2:35-41.
Jiménez TM, Patel SB, Pineda AA, Tefferi A, Owen WG: Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility. Transfusion 2003;43:328-334.
Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee C-Y, Spinelli JJ, Sutherland HJ, Tsang P, Hogge DE: Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103:333-339.
Enright H, Davis K, Gernsheimer T, McCullough JJ, Woodson R, Slichter SJ: Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003;43:1545-1552.
Yankee RA, Graff KS, Dowling R, Henderson ES: Selection of unrelated compatible platelet donors by lymphocyte HL-A matching. N Engl J Med 1973;288:760-764.
Rioux-Massé B, Cohn C, Lindgren B, Pulkrabek S, McCullough J: Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion 2014;54:3080-3087.
Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Gornbein JA, Landaw EM, Smith R, Cecka JM: Selecting donors of platelets for refractory patientson the basis of HLA antibody specificity. Transfusion 2000;40:1446-1456.
Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D: Platelet transfusion refractoriness associated with HPA‐1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001;41:984-987.
Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K: ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion 2009;49:2442-2453.
Pavenski K, Warkentin TE, Shen H, Liu Y, Heddle NM: Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study. Transfusion 2010;50:1552-1560.
Freedman J, Gafni A, Garvey M, Blanchette V: A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion 1989;29:201-207.
Tinmouth A, Tannock IF, Crump M, Tomlinson G, Brandwein J,Minden M, Sutton D: Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 2004;44:1711-1719.
Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-613.
Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL: A randomized controlled trial comparing standard-and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009;113:1564-1573.
Narvios A, Reddy V, Martinez F, Lichtiger B: Slow infusion of platelets: a possible alternative in the management of refractory thrombocytopenic patients. Am J Hematol 2005;79:80-80.
Habibi A, Esfandbod M, Ghafari MH, Khashayar P, Najafi A, Moharari RS: Platelet kinetics after slow versus standard transfusions: a pilot study. Ups J Med Sci 2011;116:212-215.
Slichter SJ: Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007;1:172-178.
Peddu P, Shah M, Sidhu P: Splenic abnormalities: a comparative review of ultrasound, microbubble-enhanced ultrasound and computed tomography. Clin Radiol 2004;59:777-792.
Santoro C, Biondo F, Baldacci E, De Propris MS, Guarini A, Paoloni F, Foà R, Mazzucconi MG: Rituximab in previously treated primary immune thrombocytopenia patients: evaluation of short- and long-term efficacy and safety. Acta Haematol 2014;132:24-29.
Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersio J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RA: A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998;91:3509-3517.
Saarinen U, Kekomaki R, Siimes M, Myllyla G: Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990;75:512-517.
MacPherson BR, Hammond P, Maniscalco C: Alloimmunization to public HLA antigens in multi-transfused platelet recipients. Ann Clin Lab Sci 1986;16:38-44.
Schiffer CA, Lichtenfeld JL, Wiernik PH, Mardiney MR, Joseph JM: Antibody response in patients with acute nonlymphocytic leukemia. Cancer 1976;37:2177-2182.
Dutcher J, Schiffer C, Aisner J, Wiernik P: Alloimmunization following platelet transfusion: the absence of a dose. Blood 1981;57:395.
Sarkodee-Adoo CB, Kendall JM, Sridhara R, Lee EJ, Schiffer CA: The relationship between the duration of platelet storage and the development of transfusion reactions. Transfusion 1998;38:229-235.
Lenhard M, Reeves GD: Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001;161:2293-2300.
Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J: Factors influencing 20-hour increments after platelet transfusion. Transfusion 1991;31:392-396.
Ganti AK, Landmark JD, Kessinger A, Smith LM, Tarantolo SR: Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. In Vivo 2006;20:559-563.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.